Insider Buying: PetVivo Holdings, Inc. (NASDAQ:PETV) CEO Acquires 150,000 Shares of Stock

PetVivo Holdings, Inc. (NASDAQ:PETV) CEO John Lai acquired 150,000 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was acquired at an average cost of $0.60 per share, for a total transaction of $90,000.00. Following the completion of the purchase, the chief executive officer now owns 1,288,592 shares in the company, valued at approximately $773,155.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

PetVivo Price Performance

Shares of NASDAQ PETV opened at $0.74 on Friday. PetVivo Holdings, Inc. has a 52 week low of $0.33 and a 52 week high of $2.90. The company’s 50-day moving average price is $1.01 and its 200 day moving average price is $1.15. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.90 and a quick ratio of 0.62.

PetVivo (NASDAQ:PETV) last issued its quarterly earnings data on Monday, February 12th. The company reported ($0.12) EPS for the quarter. The business had revenue of $0.60 million during the quarter. PetVivo had a negative net margin of 1,016.64% and a negative return on equity of 1,319.59%.

Institutional Investors Weigh In On PetVivo

Large investors have recently added to or reduced their stakes in the business. HighTower Advisors LLC acquired a new stake in PetVivo in the 1st quarter valued at about $40,000. Warberg Asset Management LLC acquired a new stake in shares of PetVivo during the 4th quarter worth about $29,000. Finally, Vanguard Group Inc. boosted its stake in shares of PetVivo by 5.2% during the 1st quarter. Vanguard Group Inc. now owns 226,137 shares of the company’s stock worth $461,000 after purchasing an additional 11,251 shares during the last quarter. 24.55% of the stock is owned by institutional investors and hedge funds.

PetVivo Company Profile

PetVivo Holdings, Inc, a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.